Tiziana Life Sciences Ltd (NASDAQ:TLSA) saw Lucid Capital Markets raise its 12-month price target on the company to $9 from $8, while maintaining a “Buy” rating, following updated clinical data for its lead drug candidate, foralumab, in multiple neuroinflammatory conditions.
In a note to clients, the firm wrote that it is “increasingly confident on the potential success of foralumab in multiple neuroinflammatory conditions.”
NanoViricides (NYSE-A:NNVC) announced the closing of its previously disclosed registered direct offering, raising about $2 million in gross proceeds before fees and expenses.
The clinical-stage antiviral drug developer sold about 1.3 million shares of common stock, or pre-funded warrants in lieu of shares, along with accompanying warrants to purchase an additional roughly 1.3 million common shares.
Ideal Power Inc (NASDAQ:IPWR, FRA:5ILA) announced that it has closed its previously announced registered direct offering with certain institutional investors, raising about $30 million in gross proceeds before expenses.
The Austin, Texas-based company sold about 5.3 million shares of common stock, or common stock equivalents, in the offering. The securities were priced at the market under Nasdaq rules, according to the company.
Montero Mining and Exploration Ltd (TSX-V:MON, OTC:MXTRF) said on Tuesday it has begun mobilization for a Phase 1 diamond drilling program at its Elvira gold project in Chile's Maricunga Gold Belt.
The Vancouver-based junior has finalized its drilling contract and completed site preparation ahead of a four-hole diamond drill program totalling up to 2,000 metres.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday that updated data from its Expanded Access Program showed intranasal foralumab continued to be well tolerated over extended treatment in patients with non-active secondary progressive multiple sclerosis (na-SPMS), with encouraging signs of disability stabilization and reduced fatigue.
The biotechnology company said data collected through March 2026, updated from an earlier March 2025 readout, covered 14 patients enrolled in the ongoing program evaluating foralumab, a fully human anti-CD3 monoclonal antibody administered intranasally.
TNR Gold Corp (TSX-V:TNR, FRA:TNW, OTC:TRRXF) said that McEwen Copper has retained Societe Generale as sole financial advisor for project debt financing at the Los Azules copper project in Argentina, a development the royalty holder called a significant step toward construction.
TNR holds a 0.4% net smelter returns royalty on Los Azules, which is owned by McEwen Copper, a company 46.3% held by McEwen Mining Inc (TSX:MUX, NYSE:MUX).
Graphene Manufacturing Group Ltd (TSX-V:GMG, OTCQX:GMGMF) announced it has signed a global distribution agreement with Curran International for its THERMAL-XR coating technology, including exclusive application services targeting the oil and gas and LNG sectors.
Under the agreement, Curran International will distribute THERMAL-XR globally and provide exclusive application services for use within oil and gas and LNG infrastructure. The company specializes in heat transfer technologies and has worked with major energy companies including ExxonMobil, BP, Chevron, Shell, Saudi Aramco, Total, and others across the sector.
Thistle Resources (TSX-V:TRCG) has started trading on the Toronto Stock Exchange Venture, as it gets started on exploration work at its Brunswick antimony project in the Bathurst Mining Camp in New Brunswick.
The company said certified trench assays at the project have returned grades of up to 10.3% antimony, 1,300 grams per tonne silver and 2.32 grams per tonne gold.
Standard Uranium Ltd (TSX-V:STND, OTCQB:STTDF, FRA:9SU0) announced that it has completed its previously announced financing, raising gross proceeds of approximately $900,000 through a listed issuer financing exemption offering.
The company said it issued 9 million units at a price of $0.10 per unit. Each unit consisted of one common share and one-half of one common share purchase warrant.
Aftermath Silver Ltd (TSX-V:AAG, OTCQX:AAGFF, FRA:FLM1) reported new assay results from its Phase 3 diamond drill program at Berenguela, with several holes returning high-grade intercepts of silver and copper from shallow depths.
Among the highlights from the silver-copper-manganese deposit in southern Peru, hole AFD165 returned 33.2 metres grading 394 grams per tonne silver, 1.19% copper, and 6.4% manganese from 46.1 metres downhole.
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has expanded its Scientific Advisory Board with the appointment of Dr. Marta Sacchetti as the company continues advancing its clinical programs in neuropathic corneal pain and inflammatory eye diseases.
The clinical-stage biopharmaceutical company is developing investigational therapies targeting neuropathic corneal pain and other inflammatory ocular conditions.
1911 Gold Corp (TSX-V:AUMB, OTCQB:AUMBF, FRA:2KY) said it has started drift development on Level 16 of its True North Mine in southeastern Manitoba as the company advances toward test mining later this year and planned production in 2027.
The company said development crews blasted their first round at the end of April in the L10 Zone, a higher-grade mineralized area accessed from Level 16, initiating work in one of the areas targeted for bulk sample and test mining activities.
Power Metallic Mines Inc (TSX-V:PNPN, FRA:IVV1, OTCQB:PNPNF) announced on Tuesday that it has entered into a strategic alliance and joint venture framework agreement with Saudi Arabia-based Amaar United Mining Company to pursue future mining license opportunities in the Kingdom.
The agreement establishes a framework under which the companies plan to jointly participate in future Saudi mining license auction rounds and other mutually agreed opportunities, with any awarded licenses expected to be developed through a 50/50 joint venture structure.
Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of its board of directors.
Bonney brings more than three decades of industry experience, including a background in multiple sclerosis and central nervous system markets. At Biogen, he held senior commercial roles and was closely involved in the launch and growth of Avonex, one of the first widely adopted therapies for relapsing forms of MS.
Ocean Power Technologies Inc (NYSE-A:OPTT) has expanded its global footprint, scaling US PowerBuoy deployments to five systems and adding autonomous surface vehicles overseas.
In the US, three of the new PowerBuoy systems are supporting Department of Homeland Security activities, with a fourth backing US Navy research and a fifth deployed with a US-based research institution.
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) announced that it has expanded its collaboration with Tate & Lyle PLC (LSE:TATE) to broaden the scope of their joint sweetener development program to include multiple plant-based sweetener molecules.
The expanded partnership builds on an agreement signed in 2024 and follows what the companies described as strong technical progress in developing sweetening solutions for food and beverage manufacturers.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has completed the last patient evaluation visit in its SUNRISE-PD Phase 2 clinical trial testing drug candidate bezisterim in early-stage Parkinson's disease, with topline results expected in the third quarter.
The NASDAQ-listed clinical-stage company said the completion of the final visit marks the start of the study closeout process.
Empire Metals Ltd (AIM:EEE, OTCQX:EPMLF) has moved a step closer to exiting a non-core gold asset after signing a definitive sale and purchase agreement for its 75% stake in the Eclipse Mining Lease near Kalgoorlie, Western Australia.
The AIM-quoted exploration and development company said total consideration for the stake is A$750,000, including a A$50,000 non-refundable deposit already received and A$700,000 payable in cash on completion.
Shares in Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF, FRA:T2X) rose 3% to 73.4p after it delivered higher first-quarter earnings as a much stronger realised gold price more than offset lower gold sales from its Segilola mine in Nigeria.
The London and Toronto-listed gold miner reported revenue of US$74.3mln for the three months to March 31, up from US$64.0mln a year earlier, while EBITDA rose to $55.8mln from $43.6mln.
Shares in Coiled Therapeutics (AIM:COIL) jumped 25% to 11p after it flagged the start to trading on the OTCQB Venture Market in the United States under the ticker COTXF.
The cross-listing allows US investors to trade the company's shares in dollars during US market hours through brokers including Fidelity, Charles Schwab and Interactive Brokers, to improve liquidity and broaden the shareholder base.
Shares in IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and biomarker analytics specialist, rose as much as 11% after interim results showed the company's order book at its highest level since 2021, prompting its house broker to describe full-year estimates as conservative.
The company reported revenue up 23% to £3.9 million in the six months to 31 March, with gross margin improving to 53.2% from 49.6% as a higher proportion of analysis-related work, which carries stronger margins, came through the mix.
A growing Ebola outbreak in central Africa has reignited investor interest in antiviral biodefence plays, helping lift shares in Island Pharmaceuticals Ltd (ASX:ILA, OTC:ILA) just as the company moves deeper into US government-linked Marburg virus programs.
ILA saw a sharp share price rally on Monday, with the stock surging more than 20% after the World Health Organization (WHO) declared an international public health emergency tied to the outbreak in the Democratic Republic of Congo and Uganda, drawing renewed market attention to Island’s antiviral candidate Galidesivir.
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), a specialist in neuroscience imaging and biomarker analytics for clinical drug trials, said it expects to deliver at least 15% revenue growth for the full year as it advances plans to open new income streams from its AI-driven platform.
Chief executive Bram Goorden said a £10 million capital raise completed in April would allow the company to accelerate a "TechBio" strategy focused on integrating its IXI platform with third-party clinical trial systems and healthcare providers, stressing the funds were not needed to sustain current operations.
European Lithium Ltd (ASX:EUR, OTCQB:EULIF) has entered a binding Scheme Implementation Deed with NASDAQ-listed Critical Metals Corp for CRML to acquire 100% of EUR’s issued share capital and listed options by way of schemes of arrangement.
Under the proposed all-scrip transaction, EUR shareholders will receive 0.035 new CRML shares, either directly or as ASX-listed CDIs, for each EUR share held. The offer implies A$0.58 per EUR share, representing a 137% premium to EUR’s last uninterrupted closing price and a 113% premium to its 20-day VWAP.
Provaris Energy Ltd (ASX:PV1, OTC:GBBLF, FRA:WS90) has strengthened plans for a compressed hydrogen export supply chain from Norway to Northern Europe after signing a co-operation agreement with Kawasaki Kisen Kaisha Ltd, known as “K” Line, and Norwegian Hydrogen.
Provaris has entered a co-operation agreement with shipping group “K” Line and Norwegian Hydrogen AS to advance a commercial hydrogen shipping solution for the FjordH2 Export Project at Ørskog in Norway.